Metagenomi (MGX) Projected to Release Earnings on Tuesday

Metagenomi (NASDAQ:MGX) is anticipated to post its Q3 2026 resultson Tuesday, November 10th. Analysts expect Metagenomi to announce earnings of ($0.6395) per share and revenue of $2.58 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Metagenomi (NASDAQ:MGX) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.18). Metagenomi had a negative return on equity of 63.65% and a negative net margin of 384.61%. The business had revenue of ($0.26) million for the quarter, compared to analyst estimates of $3.01 million. On average, analysts expect Metagenomi to post ($2.50) EPS for the current fiscal year and ($1.76) EPS for the next fiscal year.

Metagenomi Trading Up 3.3%

NASDAQ:MGX traded up $0.03 during mid-day trading on Tuesday, hitting $0.78. 19,982 shares of the company’s stock traded hands, compared to its average volume of 192,394. The firm has a market capitalization of $29.47 million, a price-to-earnings ratio of -0.32 and a beta of 0.69. The firm has a 50 day moving average of $1.03 and a two-hundred day moving average of $1.29. Metagenomi has a 12 month low of $0.72 and a 12 month high of $2.42.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Chardan Capital assumed coverage on Metagenomi in a report on Tuesday, July 7th. They set a “buy” rating and a $5.00 price target for the company. Wall Street Zen downgraded shares of Metagenomi from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 22nd. Weiss Ratings lowered shares of Metagenomi from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 22nd. Finally, Wells Fargo & Company dropped their price objective on shares of Metagenomi to $7.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $6.00.

Metagenomi Company Profile

Metagenomi, Inc is a biotechnology company focused on developing genetic medicines using genome-editing technologies. The company uses metagenomics—the study of genetic material recovered from environmental microorganisms—to discover and characterize naturally occurring CRISPR systems and other programmable enzymes that may offer advantages over conventional gene-editing tools.

Metagenomi’s technology platform is designed to support the development of therapies for genetic diseases by enabling targeted DNA editing, including gene insertion, deletion and correction.